Product Description
ADC candidate HS-20124 has entered the clinical stage, and the EGFR/c-Met ADC is expected to declare IND by the end of 2024 or early 2025. (Sourced from: https://www.moomoo.com/news/post/43030541/the-market-is-booming-as-johnson-an-innovative-drug-company?level=1&data_ticket=1724423598756466)
Mechanisms of Action: EGFR Inhibitor,C-Met Inhibitor
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Changzhou Hengbang Pharmaceutical Co., Ltd./Shanghai Hansen Biopharmaceutical Technology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|